Elanco Companion Animal Health has launched a novel prescription flea treatment for dogs which, according to the company, combines a rapid kill rate with convenient monthly oral administration.
Elanco says Comfortis Chewable Tablets for Dogs start to kill fleas within 30 minutes, providing 100 per cent control in four hours, the fastest specific claim of any approved flea preventive.
The product is based on a unique active ingredient, Spinosad, a naturally occurring fermentation product of soil bacteria with a unique insecticidal effect. Since its launch in the United States in 2007, Comfortis has established itself as the number one recommended prescription flea medication in that country and has now received European authorisation.
Elanco says the combination of its rapid action and oral method of administration is expected to prove particularly helpful in cases including:
Jannes Nijland, marketing and innovation director for Elanco Companion Animal Health in Western Europe, said: "The veterinary profession has indicated a strong desire for a prescription only flea treatment. While vets remain the 'first port of call' for advice on flea medication, our research shows that only 42 per cent of dog owners still buy their treatments from practices. We believe that the launch of an alternative approach to flea control available from practices could help vets strengthen their client relationships."
He added: "Comfortis is the first product developed and launched by Elanco Companion Animal Health in Western Europe. It is a perfect demonstration of how we intend to deliver on our mission to help veterinarians help pets live longer, healthier and higher quality lives."
For further information about Comfortis, veterinary practices should contact their Elanco key account manager, or to contact the company directly on 01256 779881
Additional information about Elanco is available at www.elanco.com and the company can be contacted via email at elancoCAH.uk@lilly.com
CVS says the new hospital, which will be based at Central Park, Avonmouth, will be custom-built with uniquely designed facilities, state-of-the-art diagnostic tools such as MRI and CT scanners, and a cutting-edge stereotactic linear accelerator for radiotherapy in cancer treatment, the only one of its kind for pets in England.
The hospital, which will open next summer, will employ over 100 people led by a team of Specialist veterinary surgeons and supported by residents, interns and registered veterinary nurses.
Planning permission has been granted for the project, and CVS is now appointing building contractors.
Richard Fairman, CEO of CVS Group, said: "We are extremely excited to be developing this innovative new specialist veterinary hospital in Bristol, providing the best animal care to pet owners across the South West. With state-of-the-art equipment and some of the highest qualified veterinary professionals, we are confident that the site will act as a centre of excellence in the veterinary world, and be a leader in Europe for cancer treatments.
"The new hospital signals our commitment to investing in cutting-edge technology to bring cancer treatment in pets to the next level. It will provide a number of employment opportunities and secure specialist veterinary skills in the Bristol area. We look forward to finalising development plans and opening the doors to pet owners in 2022."
Equibactin vet contains sulfadiazine and trimethoprim, and is indicated for use in the treatment of infections, particularly respiratory tract infections associated with Streptococcus spp. and Staphylococcus aureus; gastrointestinal infections associated with E. coli; urogenital infections associated with beta-hemolytic streptococci; and wound infections and open or drained abscesses associated with Streptococcus spp. and Staphylococcus aureus.
The new product has been designed to provide accurate administration to all sizes of horses or ponies. One syringe provides a complete dose for 600kg bodyweight and is subdivided into 12 markings, to help keep track of dosages.
Dechra Brand Manager Emma Jennings said: "Equibactin vet has a proven antibiotic combination with a synergistic effect2 making it an excellent first line broad spectrum antimicrobial treatment for most Gram positive and negative aerobes.
It can be administered without food which improves the oral bioavailability, offering equine veterinary surgeons a quick and efficient treatment when it comes to targeting these infections that are often experienced in day-to-day practice.
"With its ease of use and three-year shelf life, we anticipate that Equibactin vet will quickly become a popular product when it comes to maintaining equine health."
For more information, visit www.dechra.co.uk/products/equine.
References
In the survey of 354 owners, 65% thought their cats get on well with each other. However, 60% reported signs of disharmony, including: chasing (65%), swiping paws (53%), hissing (48%), keeping a distance from one another (31%), fighting and acting aggressively (27%), staring (30%) and sitting in front of resources to block access (25%).
In addition, some of the cats were so stressed that they would often scratch furniture or household items (46%), hide from their housemates (26%), meow excessively (20%) or spray (17%).
Claire Russell, Feliway brand manager at Ceva Animal Health, said: "There is the common misconception that cats need other feline companions, however they are naturally solitary survivors who are more than happy in their own company. Simple environmental changes and using Feliway Friends can help restore harmony between household cats who are displaying signs of multi-cat tension."
Reference
The webinar, which is presented by equine internal medicine specialist David Rendle from Rainbow Equine Hospital, challenges some of the current perceptions of worm control in horses and explains why veterinary surgeons need to engage more with horse owners on the topic to ensure a sustainable approach to parasite control.
Supported by Virbac, maker of Equimax and Eraquell horse wormers, the webinar is free to BEVA members at http://www.ebeva.org/webinar74.
The CPD-qualifying webinar is being given by Professor Saul Faust, Professor of Paediatric Immunology & Infectious Diseases at the University of Southampton, and Ian Wright MRCVS, a veterinary parasitologist, Head of ESCCAP UK & Ireland and one of the owners of The Mount Veterinary Practice in Lancashire.
The webinar will reveal the real threat of this disease and its impact on sufferers, and give an insight to the challenges of diagnosing the condition.
Register for the webinar here: https://cloud.mc.zoetis.com/beneath-the-fur-webinar
Virbac has launched a new 12 month version of Suprelorin, the reversible medical castration implant for dogs, widening the options for clients seeking an alternative to surgical castration.
Product manager Chris Geddes MRCVS said: "The launch of Suprelorin 12 gives practices the chance to offer dog owners a more convenient castration option. The implant renewal can now be included with their dog's annual boosters or health check.
"The slow-release implant is inserted at the back of the neck in the same manner as a microchip. There is no anaesthetic, no surgery and no scarring. The current implant, which contains 4.7mg active and lasts for around 6 months after insertion, will continue to be available for those wanting a more brief solution or as a trial.
"Deslorelin is a GnRH superagonist which causes suppression of LH/FSH, and therefore testosterone production, leading to temporary infertility."
For further information on Suprelorin/12, please call and ask to speak to one of our veterinary advisors on 01359 243243, or contact your local Virbac territory manager.
RSPCA has launched a new website called 'Political Animal' to encourage voters to lobby their prospective parliamentary candidates about animal welfare issues ahead of the General Election.
The site offers an interesting timeline of the last 20 years of animal welfare law, leading up to the Animal Welfare Act 2006, showing landmark changes. It also gives details of the RSPCA's stance on issues like status dogs, higher welfare farming, wild animals in circuses and animals used in experiments.
RSPCA parliamentary officer Stacey Frier, said: "The Political Animal microsite is a unique project allowing our supporters to drive the debate by letting politicians know what they want them to do for animal welfare if they are elected.
"The RSPCA and its supporters have been instrumental in campaigning for change in animal welfare legislation since the Society's creation in 1824 and we're urging the incoming parliament to continue to work with us to achieve further animal welfare milestones."
For more information, please log on to http://www.politicalanimal.org.uk/
RCVS CEO Lizzie Lockett said: "I am so proud of our performance in the Great Place to Work Awards and the efforts of everyone at the College, and especially our HR team, who have been tirelessly and creatively striving to make the College a wonderful place to work.
"Consistently being placed in the top 50 Great Places to Work is also a testament to the sustained hard work all of our employees and the important part they play in creating a supportive, interesting and good-humoured workplace.
"We are a service-led organisation and we want to make sure that we give our best to the veterinary professions and the general public. If our team enjoys the work, and the workplace, that will improve the service we are able to offer and, ultimately, benefit animal health and welfare."
Nine-year-old Nigel the puma, from Lincolnshire Wildlife Park, was suffering from a deteriorating arthritic condition, which was causing loss of function in his front leg.
His veterinary team consulted an orthopaedic specialist and trialled medical management including steroids and Solensia, but Nigel was unresponsive to treatment.
This led to a severe debilitating limp and pain, leaving a choice between amputation or euthanasia.
Nigel's treatment was funded by donations from visitors to Lincolnshire Wildlife Park, which is a registered charity that was originally established as a sanctuary for parrots in the early 1990s, who raised nearly £5,000 following a fundraising campaign.
The operation took place in a sterile theatre set up in Nigel’s enclosure, where the entire limb was removed, including the scapula.
After an intense five-hour operation, led by Iain Cope, veterinary surgeon and practice owner at Vets4Pets Newmarket, and Shannon Grimwood, veterinary nurse at Vets4Pets Newmarket, Nigel is now on the road to recovery and adapting well to life with three legs.
Iain said: “Nigel’s case was certainly unique and one we haven’t come across before. Working alongside Lincolnshire Wildlife Park and a team of local vets and veterinary nurses, we applied our knowledge of domestic cat amputations to a big one.
“The approach was extremely similar, and the operation ran as smoothly as possible.”
Instead of conducting major open surgery, Chris Shales, an RCVS and European Specialist in Small Animal Surgery, Andrew Kent, a European Specialist in Internal Medicine, and the cardiology team at Willows are using coil embolization, a minimally invasive technique which they say is far safer and less likely to lead to post-operative complications.
The procedure involves threading tiny coils, via the jugular vein, through the venous system and positioning them in the blood vessel that needs to be closed. The coils encourage the blood to form a clot and so, over time, seal the vein.
Chris said: "This procedure of treating intrahepatic portosystemic shunts is associated with a lower risk of mortality and a lower surgical morbidity rate when comparted to open surgery. The overall outcome of the two approaches is similar in terms of reduction of flow through the shunt vessel.
"Access is gained via a small incision in the neck to allow the team to operate on the liver via the jugular vein using fluoroscopy to visualise the placement of a stent within the vena cava and embolization coils within the abnormal vessel.
"Intrahepatic shunts can be extremely challenging for the surgical team to access with the result that standard, open surgical treatment of these abnormal vessels can risk life-threatening complications and animals can require a significant time to recover."
For more information about shunt surgery at Willows, contact Chris Shales or Small Animal Internal Medicine Specialist Andrew Kent on 0121 712 7070 or email enquiries@willows.uk.net.
Photo: Chris Shales, left, with Andrew Kent, centre, and cardiologist Mike Martin ('pass me a gin and tonic, would you').
Lucy and Rosanna have joined the business in hybrid positions as Novice OVs and will do this alongside working in a clinical practice.
The company says this is a significant milestone for the industry, which has relied on overseas talent for many years.
Eville & Jones says it has now developed a compelling proposition for UK new graduates who want to combine OV work with traditional clinical practice, and vets looking for a lifestyle change or a move away from practice, working flexibly in export certification, abattoir work, certification against standards, or small animal vaccination.
Charles Hartwell, chief executive officer of Eville & Jones said: “The team at Eville & Jones has spent two years developing an attractive proposition to encourage UK-educated veterinary surgeons to consider a career in this field, whether combined with traditional clinical practice, or stand alone.
"We wish Lucy and Rosanna the best of luck and hope they become trailblazers for many others to follow in their footsteps.”
Lucy said: “I’m really excited to be starting my career in veterinary public health where, as an OV, you can positively affect the lives of 1000’s of animals."
Rosanna added: “I’m really proud to have joined the veterinary industry this summer; OVs are instrumental in monitoring and safe-guarding animal welfare in a way that many vets don't realise."
A free copy of the compendium has been sent to every veterinary practice in the UK, and it is also available online at: www.noahcompendium.co.uk. A special edition of the book commissioned by AMTRA will also be available for its SQPs shortly.
NOAH chief executive Dawn Howard said: "The NOAH Compendium, in all its formats, remains a major part of NOAH’s efforts to ensure appropriate access and responsible use of medicines for all animals. We are pleased it is even more comprehensive this year, as we continue to expand its list of contributors.
"Every NOAH member, as well as the non-member participants in the NOAH Compendium, is a signatory to the NOAH Code of Practice on Promotion, which demonstrates their commitment to operate above and beyond any regulatory requirements."
She added: “As well as product datasheets, the Compendium includes another vital resource – the contact details for each participating company. Company veterinary and technical advisors have detailed knowledge about their company’s medicines. The NOAH Code includes the requirement for NCAH qualification for NOAH staff in technical dialogue with prescribers and users of animal medicines – meaning their advice can be regarded as a valuable and trusted resource. They are ready to talk to prescribers about the use of a medicine in a particular animal or in a particular situation, as well as to explain any queries about the data sheet."
Veterinary practices that have not yet received a copy, perhaps because they are new or have changed address in the past year should contact NOAH (noah@noah.co.uk).
Extra copies are also available to order, for £47.50. Special prices are also available for bulk orders.
Kriptazen is supplied with a twist-adjustable and weight-graduated dosing pump which means farmers can administer a precise dose up to 60kg without having to calculate it in ml’s first. Virbac says this will help to reduce the risk of incorrect dosing and toxicity issues.
Virbac’s Technical Product Manager Rosie Naylor said: "We are delighted to bring Kriptazen to the market. The trusted active halofuginone, along with the innovative weight graduated dosing pump, provides practices with added peace of mind when it comes to treatment."
For more information, contact your Virbac Territory Manager.
The Ear Protector sits on the back of the head and hooks onto face mask strings, pulling them backwards and away from the ears, thereby relieving pressure and stopping chafing.
The product was designed by AMufacture's Chief Operating Officer, William Howden, a former Olympic sailor who competed in the 2008 Summer Olympics in Beijing. He said: "Early in the pandemic, it became apparent to us that there was a serious need to address an unresolved problem with face masks – people were really beginning to suffer and were getting distracted from their work."
The Ear Protector is sterilisable in a dishwasher. It is also recyclable when it reaches the end of its life.
The Ear Protectors cost fifty pence each, for orders of two hundred. Contact the company direct for lower volume pricing.
For more information, visit: http://www.theearprotector.com
I invited Marc Abraham to come and answer some of the concerns raised on VetSurgeon about the ITV Pets Undercover programme.
His PR agency has instead pointed me in the direction of a response he has posted on his own website this morning. Click the link below.
http://www.marcthevet.com/response-to-%e2%80%98pets-undercover%e2%80%99/
The consultation, which was held by the College early in 2017, asked for the views of veterinary surgeons and nurses, animal owners, and stakeholders on the use of telemedicine in veterinary clinical practice.
The consultation was designed to help identify potential risks associated with telemedicine, identify areas where it may help address the needs of both clinicians and the public, and support the potential development of new professional standards and guidance.
The online survey of veterinary professionals received 1,230 responses, while the public consultation received 229 responses and the survey of organisations/stakeholders received eight responses.
The headline question asked of veterinary professionals was whether RCVS 'supporting guidance to the Code of Professional Conduct' should be amended to allow remote examination to take the place of physical examination in certain circumstances. 41% said 'Yes', 40% said 'No' and 18% were unsure.
Veterinary professionals and organisations were then asked a series of questions in order to establish how they rated the risk associated with telemedicine according to activity type, practice type, clinical sign or syndrome, mode of technology, and familiarity with client, animal or environment.
Unsurprisingly perhaps, the majority felt that providing just general advice presented a low risk. At the other end of the scale, most felt that the use of telemedicine to diagnose disease or injury would be either 'high risk', or 'not appropriate at all'.
Likewise, the majority said the risks would be low or medium where the client and environment were known and the animal seen before, for the same problem. By contrast, the majority said telemedicine would be either 'high risk' or 'not appropriate at all' when the client, animal and environment were all unknown.
When asked whether the current definition of 'under care' should be extended to allow veterinary surgeons to prescribe veterinary medicines where there has been no physical examination of the animal, 69% said 'No', 16% said 'Yes' and 15% were unsure.
However, when asked whether certain types of veterinary medicines should be able to be prescribed without a physical examination of the animal, the majority of respondents to the professional survey (52%) were in favour.
The results of the consultation were first considered at a special meeting of the Standards Committee in August 2017, where it was noted how the consultation had revealed significant confusion around current supporting guidance to the RCVS Code of Professional Conduct and that, at a minimum, clarification as to what was currently permissible was needed.
The Committee determined a key issue going forward was whether to change the Supporting Guidance to the RCVS Code of Professional Conduct regarding 'under care' to allow veterinary surgeons to prescribe POM-V medicines based on telemedicine alone.
Given the complex nature of the issues and the wide-ranging implications, the Standards Committee presented a range of options for amending RCVS Guidance to RCVS Council at its meeting in November 2017. After discussion, Council asked the Standards Committee to continue their review and to present more detailed proposals to Council regarding the future of telemedicine in clinical veterinary practice.
Anthony Roberts, RCVS Director of Leadership and Innovation, said: "We would like to thank all those who took the time to respond to the consultation – although Council has not yet made any firm decisions, we felt it would be useful to share our research so far.
"The use of telemedicine is growing rapidly in human healthcare and it is only right the RCVS assesses the opportunities it could bring to improve access to veterinary services. It is critical, however, that we understand the issues it presents 'at the coal face' and consider all the available evidence before making any changes to our Guidance. The RCVS should ensure its regulatory framework fosters innovation and maximises the opportunities to improve the quality, efficacy and accessibility of veterinary services, whilst at the same time protecting animal health and welfare."
The Standards Committee will meet again in April 2018 to take further evidence and develop proposals to take the issue forward.
Meanwhile, the full summary is available on the College’s website: www.rcvs.org.uk/telemeds-summary/.
During the webinar, which took place earlier this month, senior officers and staff from the College explained the new guidance, what it will mean for the profession, and answered questions submitted by delegates.
The webinar was chaired by RCVS President Dr Melissa Donald MRCVS with a panel comprising Standards Committee Chair Linda Belton MRCVS, RCVS Registrar Eleanor Ferguson, and RCVS Head of Standards Gemma Kingswell.
The webinar included an overview of the main changes, the considerations to take into account when prescribing POM-Vs remotely, the circumstances under which POM-Vs cannot be prescribed remotely, the prescription of antibiotics, antifungals, antiparasitics and antivirals, and how the guidance will be enforced.
Eleanor Ferguson, RCVS Registrar, said: “We have also now published a range of practice-based scenarios to help explain how the new guidance should be followed in various circumstances, and in relation to different species.
"These scenarios cover a variety of different situations, including how the guidance applies to two or more practices with mutual clients, consultancy services and the prescription of long-term controlled drugs.”
A second webinar will be held on Monday 17th July, with priority for those who wanted to attend the June webinar but were not able to do because it was over-subscribed.
www.rcvs.org.uk/undercare
Bayer Animal Health has launched Remend Wound Spray Gel for cats, dogs and horses.
The new gel contains Remend's structurally modified hyaluronic acid (HA). Bayer says it provides a matrix for cellular events that occur during the proliferative phase of the healing process, which has been shown to enhance healing1, and can promote rapid wound closure
Georgie Hollis BSc from www.vetwoundlibrary.com said: "Managing wounds can be challenging in veterinary practice; the progression of wound healing can be influenced by many factors, and selecting an appropriate product to apply should be based on the needs of the individual wound. A product that provides a moist healing environment and support of the proliferative phase ensures that cellular activity is optimised, helping to improve healing times and minimise scar tissue."
Bayer says Remend Wound Spray Gel is designed for use as part of the overall management of wounds; additional measures such as lavage, debridement and control of infection are equally important, as is giving consideration to any secondary factors that may delay healing if not addressed. The product aims to achieve greater compliance amongst owners by providing an effective management option that is easy to apply. A single application may be sufficient to enhance wound closure in fresh uncomplicated wounds; however more complex wounds may require multiple applications in order to accelerate closure.
For more information, visit: www.vetcentre.bayer.co.uk
The survey found that 51% of cat and dog owners didn't research their pets breed before buying. Of the 22% who then regretted their decision, 31% said it was because they didn’t have enough time to look after the animal, 18% because they turned out to be allergic to the animal, and 16% because they didn’t like their pet’s personality.
Apparently dog owners were more likely to regret their new pet (26%) than cat owners (16%).
Sainsbury’s has therefore launched the Pawfect Match tool, designed to help future pet owners to make informed decisions when choosing the most suitable breed for them. The pet picker asks you a number of questions about your circumstances and makes a number of suggestions based on how you answer.
Sainsbury's campaign is being fronted by Scott Miller MRCVS, who said: "I am saddened to hear that so many pet owners are regretting the animals they have chosen as companions. Dogs and cats come in all shapes and sizes, and have different temperaments. Looking after a pet is a huge commitment so it is important that people undertake adequate research before buying a pet to ensure it is a happy experience."
COMMENT
I tried Sainsbury's pet picker and it recommended a Basset Hound as the first choice. Fair enough. I always think they look like the living embodiment of the word 'hangdog', which is not really my cup of tea. Luckily, the tool makes more than one suggestion. One of the criteria I'd specified was 'quiet and calm', so the second recommendation, a whippet, was fine. But the third caught my eye. A Border Collie. What? Whaaaaaat? Quiet and calm? A Border Collie. Are you having a laugh? I thought Border Collies usually need to be sent to some sort of asylum.
Still, if Sainsbury's tool encourages more people to think harder about their choice, that's no bad thing. But they might like to rethink the Border Collie recommendation.
Charlie says that uniquely, the company offers feedback about samples submitted, with the aim of teaching veterinary staff the skills needed to interpret future samples themselves.
Cytovet is aimed at nurses and new grads who want to improve their cytology skills, vets who don’t have time to look at their own samples or have a tricky case they would like an additional opinion on, and those vets whose clients can’t afford the prices the big labs quote.
Charlie said: "I’m a vet with 16 years of clinical experience and a certAVP which focussed on small animal medicine and clinical pathology.
"I currently work in first opinion charity practice and have examined thousands of cytology samples over the years.
"I have been writing cytology reports for the practices I have worked for since 2012.
"I believe all vets and nurses should have the basic microscope skills required to help make more informed decisions for their patients, particularly in a world of escalating veterinary costs and antimicrobial resistance.
"I can examine both digital images and posted slides using a top-of-the-range trinocular digital microscope.
"All you need to do is submit the patient information and slides to me (digital images or actual slides) via my website and I will provide you with a report within 3-5 days."
Urgent turnaround is also available.
www.cytovet.co.uk
Virbac says HCA targets specific affected topical areas with negligible systemic absorption, to provide direct and rapid relief from inflammation and pruritus, delivering significant clinical improvement in atopic cases, both lesion and pruritus scores, after 14 days1.
Cortavance can be applied daily for up to 28 days and included within multimodal treatment plans for prolonged use to control atopy.
Cortavance is presented in a new ergonomic-shaped bottle allowing the user to accurately target the problem area at any angle, with its no-hand-contact spray applicators - 31ml and 76ml sizes.
For further information, contact your local Virbac Territory Manager.
Virbac has announced the launch of Carprox Vet, a carprofen-based NSAID indicated for the alleviation of post-operative pain and inflammation following orthopaedic and soft tissue surgery in dogs and cats and for the treatment of chronic pain and inflammation in dogs.
Carprox is presented as a palatable tablet for dogs in three sizes - 20 mg, 50 mg and 100 mg. An injectable 50 mg/ml solution for dogs and cats has also been launched (in bottles of 20ml).
Virbac Marketing Manager for Companion Animals Simon Boulton MRCVS said: "We launched our meloxicam-based solution for acute and chronic pain, Inflacam, in 2013. With the arrival of Carprox Vet, we are now able to offer vets a carprofen-based alternative for added flexibility and choice. We are delighted to add it to our product range and are proud to say that Virbac now offers one of the widest ranges of products for the treatment of small animals in the UK."
The study was part of a research project called VetCompass, through which the RVC, in collaboration with Vets Now, collects anonymised clinical information on over 6 million companion animals under veterinary care in the UK.
The study investigated bitches presented with difficulty giving birth (dystocia) from among almost 20,000 bitches attending 50 Vets Now surgeries. Researchers found that out of 20,000 bitches receiving emergency veterinary care, 3.7 per cent of these were treated because of difficulties encountered giving birth.
The most commonly affected breeds were the French Bulldog (15.9 times more likely), Boston Terrier (12.9 times more likely), Chihuahua (10.4 times more likely) and Pug (11.3 times more likely).
Dr Dan O’Neill, a companion animal epidemiologist within the VetCompass Programme, said: "Giving birth in dogs is not always a benign process and our research shows this risk is especially exacerbated in some common brachycephalic and toy breeds. Prospective owners should bear these welfare costs for high risk breeds in mind when choosing their new puppy."
Caroline Kisko, Kennel Club Secretary, said: 'VetCompass' research will not only enable dog breeders to make responsible breeding choices to improve the health of these dogs, it will help to highlight what puppy buyers need to be looking out for if they are intent on owning one of these breeds. If people are choosing a breed simply for its looks and are not going to a reputable breeder, they are likely to face high vet costs and a lifetime of heartache."
This study builds on previous 'purchasing' research by the RVC which found that appearance is the number one reason why owners purchase flat-faced breeds, even though their large, round, wide-set eyes, and flat rounded faces are linked with a variety of inherited diseases.
Dr Rowena Packer, lead author of the study and Research Fellow at RVC, said: "Potential puppy buyers attracted to the appearance of these breeds should seriously consider whether they are emotionally and financially prepared to take on a breed with high risks of health complications, and consider whether alternative, lower-risk breeds would better fit their lifestyle."
Running in July, the campaign aims to raise awareness of hyperthyroidism in cats and hypothyroidism in dogs, educate pet owners to spot the symptoms and thereby encourage early diagnosis.
MSD Animal Health says it hopes the campaign will increase the number of pets being taken to their veterinary practice for diagnosis, and increase both return visits and treatment compliance.
Practices supporting Pet Thyroid Month will be supplied with resources to help them educate pet owners about the two conditions.
Caroline Darouj, product manager at MSD Animal Health, said: "Although hyperthyroidism in cats and hypothyroidism in dogs are well known conditions and diagnosis is generally straightforward, a large number of vets in Europe state that both disorders are under-diagnosed, due to the fact that pet owners don’t recognise the signs.
"We wanted to launch our Thyroid Month campaign to encourage pet owners to spot the early symptoms of thyroid issues in their pets and seek advice from their veterinary practices.
"Our aim is also to benefit and educate vets and vet nurses with regard to the use of Leventa and Vidalta in treating these manageable conditions in both dogs and cats."
To find out more about Pet Thyroid Month, visit www.vidalta.co.uk